2 completed, 1 active not recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Not yet recruiting 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow TTP399: new trials by email Literature Review of TTP399 trials Research Report on TTP399
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems Cadisegliatin 800 mg QD, Placebo - Type 1 Diabetes (T1D) | Phase 2 | Not yet recruiting | vTv Therapeutics | 40 | 2026-10-01 | 2026-09-21 |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo - Diabetes Mellitus, Type 1 | Phase 3 | Active not recruiting | vTv Therapeutics | 150 | 2024-06-14 | 2026-07-28 |
| Evaluation of TTP399 in Patients With Type 1 Diabetes TTP399, Placebo Oral Tablet - Diabetes Mellitus, Type 1 | Phase 1 / Phase 2 | Completed | vTv Therapeutics | 115 | 2017-10-25 | 2023-07-03 |
| Add Glucokinase Activator to Target A1c TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg - Diabetes Mellitus, Type 2 | Phase 2 | Completed | vTv Therapeutics | 190 | 2015-03-01 | 2017-02-10 |
Diabetes Mellitus, Type 1 (3) · Diabetes Mellitus, Type 2 (1)
vTv Therapeutics (4)
United States (4) · Puerto Rico (1)
Carmen Valcarce, Ph.D. (2) · Maria Alba, MD (1) · Thomas Strack, MD (1)